Linagliptina Stada (Linagliptin)

Linagliptin is indicated for the management of type 2 diabetes mellitus, a chronic metabolic disorder characterized by insulin resistance and impaired insulin secretion.

• Type 2 diabetes mellitus: improves overall glycemic control as monotherapy or in combination with other antidiabetic agents.
• Combination with metformin: provides additional HbA1c reduction in patients whose glucose targets are not met with metformin alone.
• Patients with renal impairment: can be used without dose adjustment because the drug is eliminated primarily via the bile.

• Linagliptin reversibly inhibits the dipeptidyl peptidase‑4 (DPP‑4) enzyme, which degrades the incretin hormones GLP‑1 and GIP. By blocking DPP‑4, endogenous incretin levels rise, leading to glucose‑dependent stimulation of insulin secretion and suppression of glucagon release, thereby lowering blood glucose concentrations.

Common Side Effects

• Nasopharyngitis: mild inflammation of the upper airway.
• Headache: transient and usually mild.
• Upper respiratory tract infection: symptoms of cough and congestion.
• Dizziness: occasional light‑headed sensation.
• Gastrointestinal discomfort: includes nausea or abdominal pain.

Serious or Rare Side Effects

• Pancreatitis: severe abdominal pain requiring immediate medical attention.
• Severe allergic reactions: such as angioedema or anaphylaxis.
• Hepatic injury: elevated liver enzymes or jaundice.
• Severe skin reactions: including Stevens‑Johnson syndrome or toxic epidermal necrolysis.

Linagliptin should be used with clinical vigilance and appropriate patient counseling.

• Monitor renal function: assess kidney status even though dose adjustment is not required.
• Assess hepatic function: use with caution in patients with liver disease.
• Watch for signs of pancreatitis: discontinue if severe abdominal pain occurs.
• Evaluate cardiovascular risk: consider in patients with established heart disease.
• Store at room temperature: keep in the original container, protect from moisture and light.

Linagliptin may interact with several concomitant medicines; clinical assessment is advised.

Major Interactions (Avoid)

• Strong CYP3A4 inducers (e.g., rifampin): may markedly reduce linagliptin exposure and efficacy.
• Co‑administration with other DPP‑4 inhibitors: increases risk of hypoglycaemia.
• Use with insulin or sulfonylureas: may potentiate hypoglycaemic events.

Moderate Interactions (Monitor Closely):\n- ACE inhibitors: possible additive risk of hypotension.

• Diuretics: monitor fluid and electrolyte balance.
• NSAIDs: may affect renal function, especially in susceptible patients.